Insmed Incorporated announced positive 12-month data from an ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The data demonstrated sustained improvement across all secondary efficacy measures, including reductions in mortality risk status as measured by REVEAL Lite 2.0, and a favorable safety profile with no newly identified signals through Month 12. The study involved 91 patients, with doses up to 1,280 µg once daily permitted.

The OLE study is a non-placebo-controlled trial designed to evaluate the long-term safety, tolerability, and effectiveness of TPIP over 24 months in patients who completed lead-in TPIP PAH studies. Results showed that patients in the Placebo Crossed group (N=31) achieved similar outcomes to those in the TPIP Continued group (N=60) across all efficacy measures at Month 12. The most common treatment-emergent adverse events (TEAEs) occurring in 5.0% or more of patients included headache, cough, and nasopharyngitis.

12-Month Efficacy Results

Secondary efficacy endpoints demonstrated sustained improvement with TPIP in six-minute walk distance (6MWD), N-terminal fragment pro-B-type natriuretic peptide (NT-proBNP) concentration, and World Health Organization (WHO) Functional Class. The mean improvement from baseline for 6MWD was +55.7 meters for the TPIP Continued group and +54.1 meters for the Placebo Crossed group. NT-proBNP concentration was reduced by approximately 60% in both groups.

Approximately 65% of all patients achieved Refined Low Risk status, which is associated with a less than 5% estimated risk of mortality at three years. WHO Functional Class I or II was achieved in 78.3% of the TPIP Continued group and 80.6% of the Placebo Crossed group, with more than 25% of patients across both groups achieving WHO Functional Class I.

Safety and Tolerability

Results for the primary endpoint of safety and tolerability showed that once-daily TPIP therapy was generally well tolerated. Of the 91 patients, TEAEs occurred in 89.0% of patients, while serious TEAEs were observed in 18.7% and severe TEAEs in 16.5%. TEAEs leading to study discontinuation were experienced by 7.7% of patients. There were four deaths, none of which were considered related to TPIP treatment.

Future Development

The 12-month OLE findings support the continued clinical development of TPIP and the recent initiation of PALM-PAH, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating once-daily TPIP in patients with PAH over 24 weeks. The primary endpoint of PALM-PAH is change in 6MWD, with additional assessments of safety, tolerability, and overall efficacy. Insmed plans to publish the 12-month results from this OLE study in the future.

Wells Fargo analyst Benjamin Burnett has maintained an Overweight rating for Insmed (NASDAQ: INSM) and raised the price target to $161 from $160. The adjustment reflects a revised valuation outlook while retaining a positive stance on the biotechnology company's stock.

Analyst Rating and Price Target

The research note from Wells Fargo underscores the firm's continued confidence in Insmed's market performance. By increasing the price target modestly, the analyst signals sustained investment potential at current trading levels.

Market Context

Insmed operates in the biotechnology sector, focusing on innovative therapies. The Overweight rating and raised price target from Wells Fargo serve as indicators of the stock's perceived strength among institutional investors.